Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform ...
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage drug platform company focused on neuroinflammation and central nervous system (“CNS”) disorders. The company’s platform is centered on a resveratrol-based approach designed to safely reach therapeutic levels without the gastrointestinal side effects that can limit some resveratrol use. In practical business terms, ...Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage drug platform company focused on neuroinflammation and central nervous system (“CNS”) disorders. The company’s platform is centered on a resveratrol-based approach designed to safely reach therapeutic levels without the gastrointestinal side effects that can limit some resveratrol use. In practical business terms, Jupiter is aiming to translate that formulation/platform advantage into a pipeline of therapies that target inflammatory pathways in the nervous system—an area where there is high unmet medical need and significant competitive differentiation driven by clinical results rather than near-term product revenues.
From a products/services perspective, the company primarily operates as an R&D-driven biopharmaceutical developer. Its pipeline includes multiple clinical candidates, with several programs described as being in Phase II, such as JNS101 for Friedreich’s ataxia, JNS102 for mucopolysaccharidosis Type I, JNS107 for MELAS syndrome, and JNS108 for mild cognitive impairment and early Alzheimer’s disease. Additional development efforts include JNS109 for amyotrophic lateral sclerosis (ALS), JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19 (as described in the provided materials). These programs reflect a strategy of applying the platform across several neuroinflammatory or neurodegenerative indications.
Operationally, Jupiter is a small organization. Publicly available company data provided indicates full-time employees around 5 and LinkedIn-referenced company size in the 2–10 range, placing it in the “0–100” bucket. This scale is consistent with early-stage biotech economics, where teams are lean and much of the work is conducted through clinical operations, external CROs/manufacturing partners, and stage-gated development.
Financial/cost dynamics for a clinical-stage company typically feature recurring R&D spending and limited or no revenue from commercial products. The supplied financial multiples and profitability metrics (e.g., negative operating/EBITDA margins and negative free cash flow measures) align with the reality that such companies often do not yet generate sustainable operating cash flows and must rely on financing (equity, grants, or other capital sources) to fund clinical trials and platform development. The company’s liquidity and working-capital position can therefore be a key risk factor.
Key people are led by Founder, Chairman and CEO Christer Rosén, with other senior leadership including Alison D. Silva (President and CBO) and Saleem Elmasri (CFO), as well as co-founder and CSO Marshall Hayward (Ph.D.).
Overall, Jupiter’s stated mission is to make a significant impact for patients and society by developing therapies that address neuroinflammation. The company’s “wish” (strategically) is to progress its platform and pipeline through clinical milestones—seeking evidence of safety and efficacy that can support later-stage trials, potential regulatory pathways, and ultimately broader patient access for CNS and neuroinflammatory conditions.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$21796
—
+30.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-8.6M
-254.4%
-10.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+80.6%
—
+13.4%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-40873.2%
—
-7.5%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-39662.8%
—
+15.1%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-5.4M
-38.4%
-60.2%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-24838.2%
—
-23.3%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
-290.4%
-5663.3%
-175.3%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
0.65x
-71.8%
+29.7%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
